NHEJ Inhibitor SCR7

SCR7 is a potent and selective inhibitor of non-homologous end joining (NHEJ). It inhibits joining of DSBs in cell-free DNA repair system, blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I, thereby leading to accumulation of DSBs within the cells, culminating into cytotoxicity. SCR7 inhibits NHEJ in a Ligase IV-dependent manner within cells, and activates the intrinsic apoptotic pathway. More importantly, SCR7 impedes tumor progression in mouse models, and when co-administered with DSB-inducing therapeutic modalities it enhances their sensitivity significantly. SCR7 to target NHEJ offers a novel strategy toward the treatment of cancer and improvement of existing regimens.

5,6-bis((E)-benzylideneamino)-2-mercaptopyrimidin-4-ol
Cat no.  SCR7-50/100   50ul/100ul
Molecular Weight:334.39
C18H14N4OS
Purity:>98%
Solution:DMSO
50mM

  

---

參考文獻

Cell Volume 151, Issue 7, 21 December 2012, Pages 1474–1487

---

Nature Biotechnology 33, 538–542 (2015)